Literature DB >> 28523449

Expression of Coagulation Factor XIII Subunit A Correlates with Outcome in Childhood Acute Lymphoblastic Leukemia.

Bettina Kárai1, Zsuzsanna Hevessy1, Eszter Szánthó1, László Csáthy1, Anikó Ujfalusi1, Katalin Gyurina2, István Szegedi2, János Kappelmayer1, Csongor Kiss3.   

Abstract

Previously we identified B-cell lineage leukemic lymphoblasts as a new expression site for subunit A of blood coagulation factor XIII (FXIII-A). On the basis of FXIII-A expression, various subgroups of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) can be identified. Fifty-five children with BCP-ALL were included in the study. Bone marrow samples were obtained by aspiration and the presence of FXIII-A was detected by flow cytometry. G-banding and fluorescent in situ hybridization was performed according to standard procedures. The 10-year event-free survival (EFS) and overall survival (OS) rate of FXIII-A-positive and FXIII-A-negative patients showed significant differences (EFS: 84% vs. 61%, respectively; p = 0.031; OS: 89% vs. 61%; p = 0.008). Of all the parameters examined, there was correlation only between FXIII-A expression and 'B-other' genetic subgroup. Further multivariate Cox regression analysis of FXIII-subtype and genetic group or 'B-other' subgroup identified the FXIII-A negative characteristic as an independent factor associated with poor outcome in BCP-ALL. We found an excellent correlation between long-term survival and the FXIII-A-positive phenotype of BCP lymphoblasts at presentation. The results presented seem to be convincing enough to suggest a possible role for FXIII-A expression in the prognostic grouping of childhood BCP-ALL patients.

Entities:  

Keywords:  Factor XIII-A; Immunophenotype; Precursor B-cell acute lymphoblastic leukemia; ‘B-other’ ALL

Mesh:

Substances:

Year:  2017        PMID: 28523449     DOI: 10.1007/s12253-017-0236-0

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  36 in total

1.  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.

Authors:  E Coustan-Smith; J Sancho; M L Hancock; J M Boyett; F G Behm; S C Raimondi; J T Sandlund; G K Rivera; J E Rubnitz; R C Ribeiro; C H Pui; D Campana
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

2.  Intracellular factor XIII crosslinks platelet cytoskeletal elements upon platelet activation.

Authors:  Katherine Serrano; Dana V Devine
Journal:  Thromb Haemost       Date:  2002-08       Impact factor: 5.249

3.  Megakaryocyte-matrix interaction within bone marrow: new roles for fibronectin and factor XIII-A.

Authors:  Alessandro Malara; Cristian Gruppi; Paola Rebuzzini; Livia Visai; Cesare Perotti; Remigio Moratti; Cesare Balduini; Maria Enrica Tira; Alessandra Balduini
Journal:  Blood       Date:  2010-12-03       Impact factor: 22.113

4.  Leukemic lymphoblasts, a novel expression site of coagulation factor XIII subunit A.

Authors:  Flóra Kiss; Zsuzsanna Hevessy; Anikó Veszprémi; Eva Katona; Csongor Kiss; György Vereb; László Muszbek; J Nos Kappelmayer
Journal:  Thromb Haemost       Date:  2006-08       Impact factor: 5.249

5.  Enzyme-linked immunosorbent assay for the determination of blood coagulation factor XIII A-subunit in plasma and in cell lysates.

Authors:  E Katona E; E Ajzner; K Tóth; L Kárpáti; L Muszbek
Journal:  J Immunol Methods       Date:  2001-12-01       Impact factor: 2.303

6.  Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.

Authors:  Richard C Harvey; Charles G Mullighan; Xuefei Wang; Kevin K Dobbin; George S Davidson; Edward J Bedrick; I-Ming Chen; Susan R Atlas; Huining Kang; Kerem Ar; Carla S Wilson; Walker Wharton; Maurice Murphy; Meenakshi Devidas; Andrew J Carroll; Michael J Borowitz; W Paul Bowman; James R Downing; Mary Relling; Jun Yang; Deepa Bhojwani; William L Carroll; Bruce Camitta; Gregory H Reaman; Malcolm Smith; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2010-08-10       Impact factor: 22.113

7.  Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

Authors:  Michael N Dworzak; Gertraud Fröschl; Dieter Printz; Georg Mann; Ulrike Pötschger; Nora Mühlegger; Gerhard Fritsch; Helmut Gadner
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

8.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

Review 9.  A coagulation factor becomes useful in the study of acute leukemias: studies with blood coagulation factor XIII.

Authors:  Flóra Kiss; Agnes Simon; László Csáthy; Zsuzsanna Hevessy; Eva Katona; Csongor Kiss; János Kappelmayer
Journal:  Cytometry A       Date:  2008-03       Impact factor: 4.355

10.  Osteoblastic and vascular endothelial niches, their control on normal hematopoietic stem cells, and their consequences on the development of leukemia.

Authors:  Bella S Guerrouahen; Ibrahim Al-Hijji; Arash Rafii Tabrizi
Journal:  Stem Cells Int       Date:  2011-12-07       Impact factor: 5.443

View more
  1 in total

1.  Coagulation FXIII-A Protein Expression Defines Three Novel Sub-populations in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia Characterized by Distinct Gene Expression Signatures.

Authors:  Katalin Gyurina; Bettina Kárai; Anikó Ujfalusi; Zsuzsanna Hevessy; Gábor Barna; Pál Jáksó; Gyöngyi Pálfi-Mészáros; Szilárd Póliska; Beáta Scholtz; János Kappelmayer; Gábor Zahuczky; Csongor Kiss
Journal:  Front Oncol       Date:  2019-10-25       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.